Farewell to 2010!

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 8, 2010, Pages 797-801

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HEMOSTASIS; JOURNAL IMPACT FACTOR; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLISHING; THROMBOSIS;

EID: 78149334832     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1267031     Document Type: Editorial

References (54)

1. Schiff D, Burgess T. Editorial. Semin Thromb Hemost 2004 30 601-602
2. Favaloro E J. Editorial. Welcome to Seminars in Thrombosis and Hemostasis 2008! Semin Thromb Hemost 2008 34 1-2
3. Schiff D. Eulogy. Eberhard Mammen, M.D. 19302008. Semin Thromb Hemost 2008 34 305-306
4. Favaloro E J. Editorial. Semin Thromb Hemost 2008 34 307-308
5. Favaloro E J., Kessler C, Levi M. Editorial. Welcome to a special issue of Seminars in Thrombosis and Hemostasis the closing issue for 2008. Semin Thromb Hemost 2008 34 693-696
6. Prasad A, Kwaan H C. A tribute to Eberhard F Mammen, M.D. (19302008). Semin Thromb Hemost 2008 34 697-698
7. Favaloro E J. A tribute to Eberhard F. Mammen, M.D. (19302008). Semin Thromb Hemost 2008 34 (8) 703-707
8. Favaloro E J. Editorial. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009 35 1-2
9. Favaloro E J. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008 34 (1) 7-25
10. Favaloro E J. The journal impact factor: don't expect its demise any time soon. Clin Chem Lab Med 2009 47 (11) 1319-1324
11. Enjeti A K., Lincz L F., Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost 2007 33 (8) 771-779
12. Hayward C P., Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007 33 (3) 273-282
13. Favaloro E J. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007 33 (8) 727-744
14. Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007 33 (5) 515-523
15. Pierangeli S S., Chen P P., Raschi E et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008 34 (3) 236-250
16. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007 33 (4) 313-320
17. Sierko E, Wojtukiewicz M Z. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost 2007 33 (7) 712-721
18. Cohn D M., Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost 2007 33 (6) 573-581
19. Fareed J, Hoppensteadt D A., Fareed D et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008 34 (1) 58-73
20. Ferro V, Dredge K, Liu L et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007 33 (5) 557-568
21. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006 32 (8) 803-809
22. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008 34 (1) 39-57
23. Watson H G., Greaves M. Can we predict bleeding? Semin Thromb Hemost 2008 34 (1) 97-103
24. Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 2007 33 (4) 321-329 (Pubitemid 46878104)
25. Franchini M, Franchi M, Bergamini V, Salvagno G L., Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost 2008 34 (1) 104-112
26. Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007 33 (5) 478-487
27. Borsig L. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost 2007 33 (5) 540-546
28. Falanga A, Barbui T, Rickles F R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008 34 (2) 204-210
29. Jayandharan G R., Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008 34 (1) 128-141
30. Lippi G, Franchini M, Montagnana M, Guidi G C. Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. Semin Thromb Hemost 2007 33 (8) 759-770
31. Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost 2007 33 (6) 563-572
32. Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 2008 34 (3) 267-273
33. Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 2007 33 (4) 339-349
34. Zwicker J I. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008 34 (2) 195-198
35. Asherson R A. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost 2008 34 (3) 227-235
36. Favaloro E J., Wong R C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 2008 34 (4) 389-410
37. Milsom C, Yu J, May L, Magnus N, Rak J. Diverse roles of tissue factor-expressing cell subsets in tumor progression. Semin Thromb Hemost 2008 34 (2) 170-181
38. Prechel M, Walenga J M. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008 34 (1) 86-96
39. Sierko E, Wojtukiewicz M Z., Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 2007 33 (7) 653-659
40. Tsopanoglou N E., Maragoudakis M E. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1. Semin Thromb Hemost 2007 33 (7) 680-687
41. Wong R C., Favaloro E J. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost 2008 34 (3) 295-304
42. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007 33 (4) 350-354
43. Cunningham M T., Brandt J T., Chandler W L. et al. Quality assurance in hemostasis: the perspective from the College of American Pathologists proficiency testing program. Semin Thromb Hemost 2007 33 (3) 250-258
44. de Lamirande E. Semenogelin, the main protein of the human semen coagulum, regulates sperm function. Semin Thromb Hemost 2007 33 (1) 60-68
45. Espinosa G, Bucciarelli S, Asherson R A., Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008 34 (3) 290-294
46. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 2007 33 (7) 688-694
47. Favaloro E J. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008 34 (1) 113-127
48. Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007 33 (8) 787-797
49. Ho V T., Linden E, Revta C, Richardson P G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost 2007 33 (4) 373-388
50. Linhardt R J., Dordick J S., Deangelis P L., Liu J. Enzymatic synthesis of glycosaminoglycan heparin. Semin Thromb Hemost 2007 33 (5) 453-465
51. Lockwood C J., Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F. The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. Semin Thromb Hemost 2007 33 (1) 111-117
52. Mousa S A. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007 33 (5) 524-533
53. Palumbo J S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 2008 34 (2) 154-160
54. Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008 34 (2) 147-153